Novo Nordisk to discontinue Levemir insulin in U.S. market
(Reuters) – Novo Nordisk said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available alternatives. The Danish drugmaker said supply…
Europe will lose out on medical innovation if draft EU reforms pass, Novo Nordisk CEO says
By Maggie Fick LONDON (Reuters) – Europe will lose out to countries like the U.S. and Japan on new medical research, trials and treatments unless draft rules reforming the European pharmaceutical landscape…
Novo Nordisk sees faster profit growth on demand for diabetes drug Ozempic
By Ludwig Burger (Reuters) – Danish drugmaker Novo Nordisk raised its full-year earnings outlook on strong sales of diabetes treatment Ozempic, also reporting a better-than-expected profit. In a statement on Wednesday, it…
Obesity drug supply delay not unusual says Novo Nordisk CEO
By Nikolaj Skydsgaard COPENHAGEN – Novo Nordisk sought to soothe concerns about supplies of its new obesity drug Wegovy on Thursday, saying there was nothing unusual about a slight delay in its…
Breaking News
